Inactive Instrument

Press Releases Eisai Co., Ltd. OTC Markets

Equities

ESALY

US2825793092

Press Releases

Unlock all the news: Be the first to know and act before the market!

FDA approves a second Alzheimer's drug that can modestly slow disease	02/07	AQ
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC)	02/07	AQ
EISAI - NEW EFFICACY DATA FOR NON-CLEAR CELL RENAL CELL CARCINOMA FROM KEYNOTE-B61 ADDED TO LENVIMA US LABEL SUPPORTING KEYTRUDA + LENVIMA INDICATION FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RCC	28/06	AQ
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China	28/06	AQ
Leqembi[®] (lecanemab) launched in China	28/06	AQ
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City	21/06	AQ
Eisai : Notification Regarding Revision of “Eisai Global Code of Conduct for Business Partners”	21/06	PU
BioArctic AB - FDA accepts filing of Leqembi sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease	11/06	AQ
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease	10/06	AQ
FDA accepts filing of Leqembi[®] (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's Disease	10/06	AQ
Eisai Named to List of The Time 100 Most Influential Companies	03/06	AQ
Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform	03/06	AQ
"LEQEMBI" Lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea	28/05	AQ
Leqembi[®] approved for the treatment of Alzheimer's disease in South Korea	24/05	AQ
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024	23/05	AQ
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan	22/05	AQ
Interim Report for the period January - March 2024	17/05	AQ
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status	16/05	AQ
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status	15/05	AQ
Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 - March 2025)	15/05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Eisai Co., Ltd. OTC Markets

Equities

ESALY

US2825793092

Press Releases

Filters